New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For AAPL;JPM;RDSA;NVS;BKS;WDC;GD;VIA;VIAB;BLK;MPC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
February 25, 2015
15:50 EDTAAPLApple pivots lower, levels to watch
Subscribe for More Information
14:10 EDTNVSPharmacyclics downgraded to Hold on lack of upside at Deutsche Bank
Subscribe for More Information
13:34 EDTJPMDeutsche Bank hires JPMorgan senior banker Jeff Urwin
Subscribe for More Information
13:14 EDTAAPLFirm says iPad's market share fell sharply, Business Insider reports
Subscribe for More Information
12:54 EDTNVSPharmacyclics exploring options including sale, Bloomberg reports
According to sources, Pharmacyclics (PCYC), which develops cancer treatments, is currently exploring options, Bloomberg reports. One option may include a sale of the company, and the sources say Johnson & Johnson (JNJ) and Novartis (NVS) have expressed interest in the company. Pharmacyclics could fetch $17B-$18B in a sale, the sources add. Reference Link
12:53 EDTNVSPharmacyclics weighing sale to U.S. drugmaker, Bloomberg reports
Subscribe for More Information
12:13 EDTNVSGlaxoSmithKline sees Novartis transaction closing next week
Subscribe for More Information
11:47 EDTVIAAnalysts clash on DreamWorks following Q4 miss
The shares of animated film and television show maker DreamWorks (DWA) are rising, despite the weaker than expected results reported by the company last night. Two analysts offered very different views on the company's outlook following its results. BACKGROUND: DreamWorks last night reported a fourth quarter per share loss of ($3.08), versus analysts' consensus outlook for a ($3.01) per share loss. The company's revenue also came in below expectations. Excluding $210M in pre-tax charges associated with DreamWorks' restructuring plan, its loss was (75c) per share, the company stated. BEARISH TAKE: In a note to investors today, FBR Capital analyst Barton Crockett wrote that DreamWorks' results were "ugly," as they included $155M of write-offs on films and TV shows. However, Crockett believes that the crucial factor for the company's outlook is whether it can consistently compete with the entertainment giants, including Disney (DIS), Viacom (VIA), and Time Warner (TWX). Crockett is not convinced that DreamWorks will be able to hold its own, and he believes that its 2015 results could come in below expectations. The analyst warned that the company may have difficulty meeting its 2015 consumer products revenue guidance. DreamWorks expects its consumer products revenue to double this year, but the movie-based toy space is "very competitive" in 2015, as toys based on multiple popular children's films are set to be released, Crockett stated. Moreover, after conducting checks online, Crockett reports that there does not seem to be a great deal of interest in DreamWorks' movie "Home," which is set to be released on March 27. He kept an Underperform rating on the shares and raised his price target on the stock to $14 from $12. BULLISH TAKE: DreamWorks' results were mixed, but the results are not very important, Piper Jaffray analyst James Marsh stated. The company's guidance for its TV and consumer products businesses were solid, the analyst believes. Moreover, the company "took specific and decisive action" to avert a liquidity crunch, Marsh wrote. Specifically, DreamWorks raised $185M of capital by selling its real estate in Glendale, California and then leasing it back, and increased the size of its current credit facility to $450M from $400M, Marsh reported. The moves should "largely" eliminate investors' worries about the company's liquidity position, Marsh stated. He kept a $26 price target and Overweight rating on the stock. WHAT'S NOTABLE: On DreamWorks' earnings conference call last night, the company's CEO Jeffrey Katzenberg stated that it did not obtain more than 10% of its revenue from Netflix (NFLX) last year. However, in an SEC filing earlier this morning, DreamWorks clarified that it had obtained 14.9% of its revenue from Netflix last year. PRICE ACTION: In late morning trading, DreamWorks rose 5.6% to $22.31.
10:01 EDTAAPLIDC reports Samsung retains 22% smartphone marketshare in India
Subscribe for More Information
09:48 EDTAAPLIDC reports 96.3% smartphone marketshare for iPhone, Android
Subscribe for More Information
09:36 EDTAAPLActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL HPQ PBR FSLR MRVL TSLA LVS ABX TWTR MGM
09:25 EDTAAPLCisco, Apple among U.S. names cut from China state buying list, Reuters says
Subscribe for More Information
09:01 EDTAAPLMorgan Stanley says Apple Pay available for Wealth Management clients
Subscribe for More Information
08:47 EDTJPMJPMorgan valuation discount overdone, says Goldman
Subscribe for More Information
08:33 EDTJPMJPMorgan core franchise outlook positive, says Bernstein
Subscribe for More Information
08:07 EDTNVSNovartis' Farydak myeloma drug approved by FDA, to be distributed by Diplomat
Novartis' (NVS) drug Farydak for the treatment of patients with multiple myeloma Diplomat Pharmacy has been approved by the FDA. The drug is now a treatment option for patients with multiple myeloma who have received at least two prior regimens, including bortezomib and an immunomodulatory agent. Farydak will be distributed by Diplomat Pharmacy (DPLO).
07:27 EDTAAPLApple reportedly creating streaming music service, may relaunch iTunes, BI says
Subscribe for More Information
07:13 EDTAAPLApple price target raised to $150 from $130 at Stifel
Stifel increased its price target on Apple as the firm thinks the company "has more than enough capacity" to increase its dividend to $2.30-$2.40 per share. The firm indicates that it believes that Apple can reduce its tax rate. Stifel keeps a Buy rating on the stock.
06:23 EDTJPMJPMorgan in talks with DOJ over auto loan pricing
Subscribe for More Information
06:22 EDTAAPLJury orders Apple to pay $533M for patent violations, Reuters reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use